US FDA consults on regulatory initiatives to boost generics sector
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration is to hold a public meeting in June to identify which regulatory science initiatives it should undertake in fiscal year 2014 to support the development of generic medicines1.